Dr. Rahul Atul Parikh, MD, PhD

Dr. Parikh practices at The University of Kansas Hospital in Kansas City, Kansas, part of The University of Kansas Health System.

Dr. Parikh's NPI, 1629232913, was assigned on July 15, 2008. Dr. Parikh holds Kansas license 04-40535.

Dr. Parikh's primary practice is The University of Kansas Hospital, at 4000 Cambridge Street, Kansas City, KS 66160 in Wyandotte County. The practice phone is (913) 588-5000.

Dr. Parikh's primary practice is The University of Kansas Hospital in Kansas City, Kansas, part of The University of Kansas Health System. Dr. Parikh is also affiliated with The University of Kansas Health System Olathe Hospital. The medical group on file is KU Dental Associates. Dmand AI also links Dr. Parikh to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Parikh practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Parikh's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Parikh's licenses on file in 2 states: Kansas and Pennsylvania.

CMS data shows 1,375 Medicare services from Dr. Parikh across 9 procedure codes in 2024, for 336 Medicare patients. Medicare paid $87,782 for them.

CMS counts 336 Medicare patients who saw Dr. Parikh in 2024. The largest group is 65 to 74, with 145 patients. 75% of them have cancer, and 75% have high blood pressure. 3% are also on Medicaid. Their average risk score is 2.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Parikh's median patient age at 74, with 11% women.

In 2024, Dr. Parikh wrote 1,367 Medicare Part D claims for 200 patients. 72% of them were for generic drugs. CMS names the drug for 1,125 of them, across 28 drugs with 11 or more claims each, at $4,215,181 in total drug cost. In 2023, CMS named 1,110 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Parikh for performance year 2024, reported through an alternative payment model (APM). Dr. Parikh accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Parikh as offering telehealth.

Dmand AI links 31 papers to Dr. Parikh, published from 2010 to 2025. 2017 was the busiest year, with 2. The most frequent topics are Kidney Neoplasms, Carcinoma, Renal Cell and Telemedicine. Dr. Parikh has published most often in PLoS One. Dr. Parikh's most frequent co-authors are Leonard Joseph Appleman, MD, Tala Achkar and Ali Imran Amjad, MD.

Dmand AI links Dr. Parikh to 10 clinical trials, 6 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Carcinoma, Transitional Cell, Prostatic Neoplasms and Ureteral Neoplasms. National Cancer Institute (NCI) sponsors the most, 6.

CMS Open Payments shows 38 general payments to Dr. Parikh from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 44% of the total. Bristol-Myers Squibb Company paid the most, $4,654. It also lists 1 research payment totaling $35 in 2016.